Yayın:
Proteasome inhibitor immunotherapy for the epithelial to mesenchymal transition: assessing the A549 lung cancer cell microenvironment and the role of M1, M2a and M2c ‘hydrocortisone-polarised’ macrophages

Sadeleştirilmiş öğe sayfası
dc.contributor.authorDikmen, Miriş
dc.contributor.authorMiriş Dikmen
dc.contributor.orcid0000-0003-1534-8117
dc.contributor.orcid0009-0000-1090-0166
dc.date.accessioned2025-11-13T10:22:44Z
dc.date.issued2022-03-13
dc.identifier.doi10.1007/s11033-022-07329-w
dc.identifier.endpage4793
dc.identifier.issn0301-4851
dc.identifier.issue6
dc.identifier.openalexW4220955609
dc.identifier.startpage4777
dc.identifier.urihttps://hdl.handle.net/11421/3968
dc.identifier.urihttps://doi.org/10.1007/s11033-022-07329-w
dc.identifier.volume49
dc.language.isoen
dc.relation.ispartofMolecular Biology Reports
dc.rightsrestrictedAccess
dc.subjectA549 cell
dc.subjectCancer research
dc.subjectEpithelial–mesenchymal transition
dc.subjectVimentin
dc.subjectLung cancer
dc.subjectTumor microenvironment
dc.subjectProteasome inhibitor
dc.subjectCancer cell
dc.subjectCancer
dc.subjectMetastasis
dc.subjectChemistry
dc.subjectImmunotherapy
dc.subjectApoptosis
dc.subjectImmunology
dc.subjectMedicine
dc.subjectPathology
dc.subjectInternal medicine
dc.subjectImmunohistochemistry
dc.subjectBiochemistry
dc.subject.sdg3
dc.titleProteasome inhibitor immunotherapy for the epithelial to mesenchymal transition: assessing the A549 lung cancer cell microenvironment and the role of M1, M2a and M2c ‘hydrocortisone-polarised’ macrophages
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5042645402

Dosyalar

Koleksiyonlar

Publications